UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 7 July 2025, London UK
GSK completes acquisition of efimosfermin, a potential
best-in-class specialty medicine to treat and prevent progression
of steatotic liver disease (SLD)
GSK plc (LSE/NYSE: GSK) today announced the completion of
its previously
announced acquisition
of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a
phase III-ready, potential best-in-class investigational specialty
medicine aimed at treating and preventing the progression of
SLD.
Efimosfermin is a novel, once-monthly fibroblast growth factor 21
(FGF21) analog therapeutic in clinical development for the
treatment of metabolic dysfunction-associated steatohepatitis
(MASH), including cirrhosis, and future development in
alcohol-related liver disease (ALD), both forms of SLD. Currently,
MASH and ALD have limited treatment options and are the leading
causes of liver transplant in the US, representing a significant
burden and cost on healthcare utilisation.1
GSK, based on its work in human genetics and disease phenotyping,
believes efimosfermin has potential to address more advanced stages
of SLD due to its direct antifibrotic mechanism of action, and sees
opportunity in combination with GSK'990, a siRNA therapeutic in
development for other subsets of patients with SLD.
Kaivan Khavandi, SVP & Global Head, Respiratory, Immunology
& Inflammation R&D, GSK said:
"The close of our acquisition for efimosfermin alfa represents a
significant expansion of our hepatology pipeline aimed at
addressing steatotic and viral drivers of liver disease.
Efimosfermin is a key growth opportunity for GSK with multiple
development options and potential first launch in 2029. We look
forward to unlocking the potential of this medicine for
patients."
GSK is driving innovation for a range of immune-mediated conditions
by harnessing the science of the immune system and advanced
technologies. The addition of efimosfermin further expands GSK's
pipeline to address fibro inflammatory diseases in liver, lung and
kidney, a key focus for the company.
Financial considerations
GSK has acquired BP Asset IX, Inc., a subsidiary of Boston
Pharmaceuticals, to access efimosfermin. The total cash
consideration for this acquisition amounts to up to $2 billion,
comprising an upfront payment of $1.2 billion and up to $800
million in success-based milestone payments. GSK will also be
responsible for success-based milestone payments as well as tiered
royalties for efimosfermin owed to Novartis Pharma AG.
About efimosfermin alfa
Efimosfermin is an investigational, once-monthly subcutaneous
injection of a long-acting variant of FGF21 that is designed to
regulate key metabolic pathways to decrease liver fat, ameliorate
liver inflammation, and reverse liver fibrosis in patients with
MASH. Efimosfermin is currently in trials for moderate to
advanced fibrosis, including cirrhosis and is not approved anywhere
in the world.
About Boston Pharmaceuticals
Boston Pharmaceuticals is a clinical-stage biopharmaceutical
company that leverages an experienced and committed drug
development team to advance a portfolio of highly differentiated
therapies that may address important unmet medical needs in serious
liver diseases. Boston Pharmaceuticals is a portfolio company
of B-Flexion, a private, entrepreneurial investment firm which
manages the combined funds and investments associated with the
Bertarelli family and also partners with sophisticated capital to
meet the shared goal of delivering exceptional value over the
generations, while also contributing positively to
society.
About GSK research in hepatology
GSK is currently investigating multiple potential treatments for
patients with liver disease, including treatments for chronic
hepatitis B, alcohol-related liver disease (ALD), and metabolic
dysfunction-associated steatohepatitis (MASH).
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Sarah Clements
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q1 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
1 Younossi et al. Hepatol Commun. 2023 Dec
22;8(1):e0352
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
07, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|